NOVO HOLDINGS LAUNCHES USD 165M IMPACT FUND TO COMBAT ANTIMICROBIAL RESISTANCE

Antimicrobial resistance is a global threat to human health. Novo Holdings today announces the launch of an impact fund commissioned by the Novo Nordisk Foundation with a total budget of USD 165 million to invest in companies involved in discovering and early-stage development of therapies to combat antimicrobial resistance.

• Source: novonordiskfonden.dk
• 477
• March 7, 2018